Cardiovascular Diagnostics: Key Developments in Technologies and Markets

Executive Summary

Cardiovascular Imaging: Trends and Implications

In Vitro Cardiovascular Diagnostics: Trends and Implications

Chapter 1. Background Trends in Cardiovascular Disease

1.1 Cardiovascular Disease Statistics

Coronary Heart Disease

Congestive Heart Failure

Hypertension

Stroke

Cardiac Arrhythmias

Other Cardiovascular Disease

1.2 Prospects for Cardio-Theranostics

Chapter 2. Cardiovascular Imaging

2.1 Ultrasound

Competition

Market Trends and Developments

2.2 Magnetic Resonance

Competition

Market Trends and Developments

2.3 Computed Tomography

Competition

Market Trends

2.4 Nuclear Medicine

SPECT Imaging

-Competition and Market Trends

PET Imaging

-Competition and Market Trends

Chapter 3. Biomarkers for Cardiovascular Diagnostics

3.1 Biomarkers for Determining Risk in Coronary Artery Disease (CAD)

Description of Biomarkers for Risk of CAD

-C-Reactive Protein

-Lp-PLA2

-Homocysteine

-LDL Subclasses and Particle Size

-Lipoprotein (a)

-Apolipoprotein A and Apolipoprotein B

Medical and Economic Impact

Competition and Outlook

3.2 Biomarkers For Diagnosis of Acute Coronary Syndrome

Description of Current Markers for Acute Coronary Syndrome

-Creatine Kinase MB Isoenzymes (CK-MB)

-Troponin I and Troponin T

-Myoglobin

-Heart Fatty Acid Binding Proteins

-Ischemia-Modified Albumin

Potential Future Biomarkers for Acute Coronary Syndrome

-Blood Choline

-CD40 Ligand

-Chemoattractant Biomarkers

-Glutathione Peroxidase 1

-Myeloperoxidase

-Pregnancy-Associated Plasma Protein-A

-Serum Deoxyribonuclease I Activity

-Unbound Free-Fatty Acids

Medical and Economic Impact

Competition and Outlook

Biomarkers for Congestive Heart Failure

-Medical and Economic Impact

-Competition and Outlook

3.4 Thrombosis Markers

Description of Biomarkers and Genetic Markers

-D-Dimer

-Factor V Leiden

-Prothrombin Factor II (PT 20210A)

-Methylene-tetra-hydro-folate-reductase (MTHFR) Gene

-Plaminogen Activator Inhibitor-1

Medical and Economic Impact

Competition and Outlook

3.5 Potential Future Markers for Stroke

Description of Potential Stroke Markers

-Neuron-Specific Enolase

-S-100B

-Matrix Metalloproteinases

-Stroke Panel

Medical and Economic Impact

Competition and Outlook

3.6 Cardio-Theranostics

Pharmacogenetics

-Cytochrome P450

-CYP2D6

-CYP2C9

-Cholesterol Ester Transfer Protein

-Angiotensin-Converting Enzyme Gene

-Beta-1 and Beta-2 Adrenergic Receptor Gene

-N-Acetyltransferase-2 Gene

-Platelet Fc-Gamma-Receptor Gene

-Alpha-Adducin Gene Variant

-Apolipoprotein E Genotyping

Other Cardio-Theranostics

-Antiplatelet Drug Testing

-Aspirin Resistance Test

Medical and Economic Impact

Competition and Outlook

Chapter 4. Expert Interviews

Cardiovascular In Vitro Diagnostic Interviews

-Alberto Abate, bioMérieux

-Kenneth F. Buechler, PhD, Biosite

-Hans-Juergen Loyda, Roche Diagnostics

-David Ludvigson, Nanogen, Inc.

--Biomarker Tests

--Genomic Testing

-- New Biomarkers

Cardiovascular Imaging Interviews

-James Kronauge, PhD, Molecular Insight

-Gregg Mayer, EPIX Pharmaceuticals

Chapter 5. Company Profiles

Abaxis

Abbott Diagnostics

Atherotech

Bayer HealthCare

Beckman Coulter

Berlex Laboratories, Inc.

bioMérieux SA

Biosite

Bracco Diagnostics

Bristol Myers Squibb Medical Imaging

Cholestech

Dade Behring

Diagnostic Products Corp. (DPC)

GE Healthcare

Instrumentation Laboratory

International Technidyne Corp (ITC)

Ischemia Technologies

LipoScience

Mallinkrodt

Nanogen

Ortho Clinical Diagnostics

Philips Medical Systems

Response Biomedical

Roche Diagnostics

Siemens Medical Solutions

Spectral Diagnostics

Sysmex

Third Wave Technology

References

Index